From CNBC · Annika Kim Constantino · · 1m 10s
Merck CEO: Cancer Vaccine Manufacturing Timeline Shortens
Merck CEO says cancer vaccine production will speed up over time with Moderna.
In brief
Merck CEO says cancer vaccine production will speed up over time with Moderna. Merck CEO Rob Davis expects the company's personalized cancer vaccine with Moderna to become faster to manufacture as the process matures. Originally reported by CNBC.
Merck CEO Rob Davis
Merck CEO Rob Davis told CNBC he expects the company's breakthrough cancer vaccine with Moderna to get faster to manufacture over time.
“We are going to drive for improvement, but right now the focus really is, let's make sure we have the supply ready, we have the market ready to bring this important innovation to the market, and then we'll talk about how do we accelerate.”
Manufacturing Process
Davis acknowledged that manufacturing the vaccine is a complex system but said Merck and Moderna have the process down to a very tight science.
“I'm actually very confident that we're not going to have complexities in getting this to patients in a very timely fashion.”
New Research Facility
Merck opened a new 120,000-square-foot research facility named Advance in West Point, Pennsylvania.
“Pennsylvania Gov. Josh Shapiro joined Merck executives and other government officials for a ribbon-cutting ceremony to celebrate the launch of the facility.”
Keytruda Patent Timeline
Keytruda's core U.S. compound patent expires in December 2028, while secondary patents extend protection into 2029 and beyond.
“Merck has implemented a multi-layered strategy to turn the Keytruda transition into what it views as a manageable hill rather than a sharp revenue cliff.”
Legal Battle Over Keytruda
A Dutch court blocked Merck from selling subcutaneous Keytruda in eight European countries due to a patent infringement suit.
“Merck has said it strongly disagrees with the rulings and plans to appeal.”
New Drug Approvals
Merck approved Winrevair for a rare lung disease and Lipfendra for cholesterol last month.
“Winrevair, a treatment for a rare, life-threatening lung disease, was approved in 2024 and acquired through its $11.5 billion acquisition of Acceleron.”
What Happens Next
Merck aims to accelerate cancer vaccine production while managing Keytruda's patent expiration and legal challenges.
“We're moving in a direction with technology that's really unprecedented.”
The one thing
Merck CEO Rob Davis expects the company's personalized cancer vaccine with Moderna to become faster to manufacture as the process matures.
